Mononitrates

1. Front Matter

   Pages I-XI

   PDF

2. Preface

   1. Preface

      • Jay N. Cohn

      Pages 1-2

3. Introductory Remarks on the Development of Isosorbide-5-Mononitrate

   1. Introductory Remarks on the Development of Isosorbide-5-Mononitrate

      • U. Abshagen

      Pages 3-4

4. Vasodilation with Nitrates

   1. Front Matter

      Pages 5-5

      PDF

   2. Nitrates: Mechanism of Vasodilation

      • R. Zelis

      Pages 7-16

   3. Effect of Different Vasodilators on Epicardial Coronary Arteries

      • E. Bassenge, U. Pohl, J. Holtz

      Pages 17-22

   4. Effects of Isosorbide-5-Mononitrate on Hemodynamic Parameters and on Regional Myocardial Ischemia in Conscious Dogs

      • K. Strein, E. Voss, G. Sponer, B. Müller-Beckmann, E. Roesch

      Pages 23-33

   5. Isosorbide-5-Mononitrate Increases Cyclic Guanosine Monophosphate Concentration in Rat Aorta in Vitro and in Vivo

      • W. Bartsch, K. Strein, E. Böhm, G. Sponer, B. Müller-Beckmann

      Pages 34-38

   6. Activation of Counter-Regulatory Mechanisms on Administration of Equipotent Doses of Different Types of Vasodilators to Conscious Dogs

      • G. Sponer, E. Mierzwa, K. Strein, B. Müller-Beckmann

      Pages 39-44

   7. Differences in the Metabolism of Isosorbide-5-Mononitrate and Isosorbide Dinitrate and Their Consequences for Toxicologic Findings

      • K. Strein, G. Sponer, W. Bartsch

      Pages 45-49

5. Clinical Pharmacology

   1. Front Matter

      Pages 51-51

      PDF

   2. Pharmacokinetics of ISDN, Sustained-Release ISDN, and IS-5-MN

      • U. Abshagen

      Pages 53-66

   3. Vascular Pharmacokinetics of Nitrates

      • H.-L. Fung, S. C. Sutton, A. Kamiya

      Pages 67-72

   4. Effect of Glyceryl Trinitrate, Isosorbide-5-Mononitrate, and Propranolol on Apparent Liver Blood Flow

      • P. C. Hayes, L. Morrison, I. A. D. Bouchier

      Pages 73-77

   5. Kinetics of IS-5-MN and Its Glucuronide in Patients with Renal Failure

      • F. Raue, E. Ritz, W. Akpan, R. Endele, G. Neugebauer

      Pages 78-85

   6. Pharmacokinetics of IS-5-MN after Oral and Intravenous Administration in Patients with Hepatic Failure

      • W. Akpan, R. Endele, G. Neugebauer, H. Steudel

      Pages 86-91

6. Tolerance to Nitrates

   1. Front Matter

      Pages 93-93

      PDF

   2. Nitrate Tolerance: Animal Experiments and Clinical Studies in Heart Failure

      • P. W. Armstrong, J. A. Moffat

      Pages 95-100

   3. Development and Disappearance of Tolerance to Organic Nitrates in Conscious Dogs

      • G. Sponer, K. Strein

      Pages 101-106

   4. Tolerance and Rebound Phenomena in Nitrate Therapy

      • H. Ohlmeier, H. M. Mertens, H. Mannebach, U. Gleichmann

      Pages 107-123

The nitrates have remarkable clinical effects that have stood the test of time in the management of ischemic heart disease. What is unusual about this class of com­ pounds is that, after many years of clinical use, we are still exploring new avenues as to the vascular mechanisms of their effect, their applications in treating other clini­ cal conditions, and the development of products with more favorable pharmacoki­ netic properties. This volume represents the proceedings of a symposium held June 14-16, 1984, in Montreux. The papers were selected to explore the current state of knowledge re­ garding the mechanisms of action, pharmacokinetics, and clinical efficacy of ni­ trates. Particular attention has been given to newer studies utilizing the 5-mononi­ trate metabolite of isosorbide dinitrate, a drug whose pharmacokinetic properties may make it an important new agent in the treatment of angina and congestive heart failure. One of the benefits of an international meeting of experts sharing their views on an internationally used group of drugs is that differences in concepts and clinical practice become apparent and can be discussed. The Montreux forum made it clear that clinicians in North and South America and Europe have diverging views on how the nitrates should be used.

• Nitrat
• anatomy
• angina pectoris
• coronary artery disease
• depression
• drug
• heart
• kinetics
• metabolism
• pharmacokinetics
• pharmacology
• research

• Cardiovascular Division, University of Minnesota, Minneapolis, USA

  Jay N. Cohn

• Product Development, Boehringer Mannheim GmbH, Mannheim 31, Federal Republic of Germany

  Reiner Rittinghausen

Policies and ethics